Page last updated: 2024-12-05

garcinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

garcinol: from stem bark of Garcinia huillensis; has chemotherapeutic activity against gram-positive & gram-negative cocci, mycobacteria & fungi [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
GarciniagenusA plant genus of the family CLUSIACEAE. Members contain XANTHONES.[MeSH]ClusiaceaeThe mangosteen plant family (sometimes classified as Guttiferae; also known as Hypericaceae) of the order THEALES, subclass Dilleniidae, class Magnoliopsida. It includes trees and shrubs with resinous, sticky sap, usually with broad-ended, oblong, leathery leaves with a strong, central vein, flowers with many stamens.[MeSH]

Cross-References

ID SourceID
PubMed CID5281560
CHEBI ID5276
SCHEMBL ID14917227
MeSH IDM0154094

Synonyms (11)

Synonym
garcinol
C09929 ,
78824-30-3
chebi:5276 ,
SCHEMBL14917227
(1r,5r,7r)-3-(3,4-dihydroxybenzyol)-4-hydroxy-8,8-dimethyl-1,7-bis(3-methyl-2-buten-1-yl)-5-[(2s)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]bicyclo[3.3.1]non-3-ene-2,9-dione
(1s,3z,5r,7r)-3-[(3,4-dihydroxyphenyl)-hydroxy-methylene]-1-[(2s)-2-isopropenyl-5-methyl-hex-4-enyl]-6,6-dimethyl-5,7-bis(3-methylbut-2-enyl)bicyclo[3.3.1]nonane-2,4,9-trione
mfcd03700761
CS-0028887
HY-107569
MS-30635

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" However, compared to other structurally similar phytochemicals like garcinol and curcumin, the therapeutic use of chalcones is limited because of their lower bioavailability and rapid metabolic clearance from biological system."( Fluorinated 2'-hydroxychalcones as garcinol analogs with enhanced antioxidant and anticancer activities.
Ahmad, A; Dandawate, P; Deshpande, J; Oswal, N; Padhye, S; Rub, RA; Sarkar, FH; Swamy, KV, 2010
)
0.36
" The most widely used MAO-B inhibitor to maintain the bioavailability of dopamine in the brain of PD patients is L-deprenyl, despite of its potential side-effects."( Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease.
Bhattacharya, P; Borah, A; Chakrabarty, J; Dutta, A; Mazumder, MK; Paul, R; Phukan, BC, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
"05% garcinol for 5 weeks, starting 1 week before the first dosing of AOM."( Prevention of colonic aberrant crypt foci by dietary feeding of garcinol in male F344 rats.
Ariga, T; Kagami, S; Kataoka, S; Kohno, H; Koshimizu, K; Murakami, A; Ohigashi, H; Shimada, R; Tanaka, T; Yamaguchi, F, 2000
)
0.31
" To reduce the daily dosing of L-DOPA in patients, inhibitors of dopamine catabolizing enzymes, particularly monoamine oxidase-B (MAO-B), are prescribed."( Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease.
Bhattacharya, P; Borah, A; Chakrabarty, J; Dutta, A; Mazumder, MK; Paul, R; Phukan, BC, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (150)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (0.67)18.2507
2000's26 (17.33)29.6817
2010's96 (64.00)24.3611
2020's27 (18.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.31%)5.53%
Reviews7 (4.58%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other144 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]